The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis

Histology and Histopathology

Volumn 25, Issue 5, 2010, Pages 669-680

  Martelli, Alberto M ^a,b   Chiarini, Francesca ^a   Evangelisti, Camilla ^a   Grimaldi, Cecilia ^a   Ognibene, Andrea ^c   Manzoli, Lucia ^a   Billi, Anna Maria ^a   McCubrey, James A ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CNR   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Differentiation; Hematopoietic stem cells; PI3K Akt mTOR; Proliferation; Signal transduction

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; ERYTHROPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; METABOLISM; MYELOPOIESIS; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPOIESIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ERYTHROPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; MYELOPOIESIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THROMBOPOIESIS;

EID: 77953043118     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Akashi K., Traver D., Miyamoto T. and Weissman I.L. (2000). A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193-197.
2. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., Danino M., Karlan B.Y. and Slamon D.J. (2003). Overexpression of AKT2/protein kinase B, leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63, 196-206.
3. Arcasoy M.O. and Jiang X. (2005). Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. Br. J. Haematol. 130, 121-129.
4. Backer J.M. (2008). The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem. J. 410, 1-17.
5. Bae S.S., Cho H., Mu J. and Birnbaum M.J. (2003). Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. J. Biol. Chem. 278, 49530-49536.
6. Baker S.J., Rane S.G. and Reddy E.P. (2007). Hematopoietic cytokine receptor signaling. Oncogene 26, 6724-6737.
7. Bakker W.J., van Dijk T.B., Parren-van Amelsvoort M., Kolbus A., Yamamoto K., Steinlein P., Verhaak R.G., Mak T.W., Beug H., Lowenberg B. and von Lindern M. (2007). Differential regulation of Foxo3a target genes in erythropoiesis. Mol. Cell. Biol. 27, 3839-3854.
8. Bhaskar P.T. and Hay N. (2007). The two TORCs and Akt. Dev. Cell 12, 487-502.
9. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W. and Holland E.C. (2009). PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235.
10. Bouscary D., Lecoq-Lafon C., Chretien S., Zompi S., Fichelson S., Muller O., Porteu F., Dusanter-Fourt I., Gisselbrecht S., Mayeux P. and Lacombe C. (2001). Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo). Oncogene 20, 2197-2204.
11. Bouscary D., Pene F., Claessens Y.E., Muller O., Chretien S., Fontenay-Roupie M., Gisselbrecht S., Mayeux P. and Lacombe C. (2003). Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 101, 3436-3443.
12. Bozulic L. and Hemmings B.A. (2009). PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr. Opin. Cell Biol. 21, 256-261.
13. Brazil D.P., Yang Z.Z. and Hemmings B.A. (2004). Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29, 233-242.
14. Brognard J. and Newton A.C. (2008). PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol. Metab. 19, 223-230.
15. Buitenhuis M., Verhagen L.P., van Deutekom H.W., Castor A., Verploegen S., Koenderman L., Jacobsen S.E. and Coffer P.J. (2008). Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 111, 112-121.
16. Campone M., Levy V., Bourbouloux E., Berton Rigaud D., Bootle D., Dutreix C., Zoellner U., Shand N., Calvo F. and Raymond E. (2009). Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br. J. Cancer 100, 315-321.
17. Chabanon A., Desterke C., Rodenburger E., Clay D., Guerton B., Boutin L., Bennaceur-Griscelli A., Pierre-Louis O., Uzan G., Abecassis L., Bourgeade M.F., Lataillade J.J. and Le Bousse-Kerdiles M.C. (2008). A cross-talk between stromal cell-derived factor-1 and transforming growth factor-beta controls the quiescence/cycling switch of CD34(+) progenitors through FoxO3 and mammalian target of rapamycin. Stem Cells 26, 3150-3161.
18. Chen C., Liu Y., Liu R., Ikenoue T., Guan K.L., Liu Y. and Zheng P. (2008). TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J. Exp. Med. 205, 2397-2408.
19. Crazzolara R., Cisterne A., Thien M., Hewson J., Baraz R., Bradstock K.F. and Bendall L.J. (2009). Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113, 3297-3306.
20. DiNitto J.P. and Lambright D.G. (2006). Membrane and juxtamembrane targeting by PH and PTB domains. Biochim. Biophys. Acta 1761, 850-867.
21. Dolznig H., Boulme F., Stangl K., Deiner E.M., Mikulits W., Beug H. and Mullner E.W. (2001). Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays. FASEB J. 15, 1442-1444.
22. Downward J. (2004). PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 15, 177-182.
23. Drayer A.L., Olthof S.G. and Vellenga E. (2006). Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors. Stem Cells 24, 105-114.
24. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.M., Garcia-Echeverria C., Schultz P.G. and Reddy V.A. (2009). The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA 106, 268-273.
25. Dunlop E.A. and Tee A.R. (2009). Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell. Signal. 21, 827-835.
26. Eichhorn P.J., Creyghton M.P. and Bernards R. (2009). Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 1795, 1-15.
27. Elliott S., Pham E. and Macdougall I.C. (2008). Erythropoietins: a common mechanism of action. Exp. Hematol. 36, 1573-1584.
28. Engstrom M., Karlsson R. and Jonsson J.I. (2003). Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand. Exp. Hematol. 31, 316-323.
29. Eyler C.E., Foo W.C., LaFiura K.M., McLendon R.E., Hjelmeland A.B. and Rich J.N. (2008). Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 26, 3027-3036.
30. Fonseca B.D., Smith E.M., Lee V.H., MacKintosh C. and Proud C.G. (2007). PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem. 282, 24514-24524.
31. Franke T.F. (2008). PI3K/Akt: getting it right matters. Oncogene 27, 6473-6488.
32. Friedman A.D. (2007). Transcriptional control of granulocyte and monocyte development. Oncogene 26, 6816-6828.
33. Fruman D.A. and Bismuth G. (2009). Fine tuning the immune response with PI3K. Immunol. Rev. 228, 253-272.
34. Fuhler G.M., Tyl M.R., Olthof S.G., Lyndsay Drayer A., Blom N. and Vellenga E. (2009). Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells. Eur. J. Haematol. 83, 235-245.
35. Gallia G.L., Tyler B.M., Hann C.L., Siu I.M., Giranda V.L., Vescovi A.L., Brem H. and Riggins G.J. (2009). Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol. Cancer Ther. 8, 386-393.
36. Gan B., Sahin E., Jiang S., Sanchez-Aguilera A., Scott K.L., Chin L., Williams D.A., Kwiatkowski D.J. and DePinho R.A. (2008). mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc. Natl. Acad. Sci. USA 105, 19384-19389.
37. Geddis A.E., Fox N.E. and Kaushansky K. (2001). Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors. J, Biol, Chem. 276, 34473-34479.
38. Geest C.R., Zwartkruis F.J., Vellenga E., Coffer P.J. and Buitenhuis M. (2009). Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells. Haematologica 94, 901-910.
39. Ghaffari S., Kitidis C., Zhao W., Marinkovic D., Fleming M.D., Luo B., Marszalek J. and Lodish H.F. (2006). AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 107, 1888-1891.
40. Grech G., Blazquez-Domingo M., Kolbus A., Bakker W.J., Mullner E.W., Beug H. and von Lindern M. (2008). Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation. Blood 112, 2750-2760.
41. Greer E.L. and Brunet A. (2005). FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410-7425.
42. Guerriero R., Parolini I., Testa U., Samoggia P., Petrucci E., Sargiacomo M., Chelucci C., Gabbianelli M. and Peschle C. (2006). Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J. Cell Sci. 119, 744-752.
43. Guertin D.A., Stevens D.M., Saitoh M., Kinkel S., Crosby K., Sheen J.H., Mullholland D.J., Magnuson M.A., Wu H. and Sabatini D.M. (2009). mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148-159.
44. Guo W., Lasky J.L., Chang C.J., Mosessian S., Lewis X., Xiao Y., Yeh J.E., Chen J.Y., Iruela-Arispe M.L., Varella-Garcia M. and Wu H. (2008). Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 453, 529-533.
45. Harrison D.E., Astle C.M. and Delaittre J.A. (1978). Loss of proliferative capacity in immunohemopoietic stem cells caused by serial transplantation rather than aging. J. Exp. Med. 147, 1526-1531.
46. Haseyama Y., Sawada K., Oda A., Koizumi K., Takano H., Tarumi T., Nishio M., Handa M., Ikeda Y. and Koike T. (1999). Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis. Blood 94,1568-1577.
47. Hazen A.L., Smith M.J., Desponts C., Winter O., Moser K. and Kerr W.G. (2009). SHIP is required for a functional hematopoietic stem cell niche. Blood 113, 2924-2933.
48. Helgason C.D., Antonchuk J., Bodner C. and Humphries R.K. (2003). Homeostasis and regeneration of the hematopoietic stem cell pool are altered in SHIP-deficient mice. Blood 102, 3541-3547.
49. Hong L., Ramdas B., Chen J., Harris C., Wojchowski D.M. and Kapur R. (2008). KIT associated intracellular tyrosines play an essential role in EpoR co-signaling. Cell. Signal. 20, 1513-1520.
50. Hong S.P., Leiper F.C., Woods A., Carling D. and Carlson M. (2003). Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl. Acad. Sci. USA 100, 8839-8843.
51. Horn S., Bergholz U., Jucker M., McCubrey J.A., Trumper L., Stocking C. and Basecke J. (2008). Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene 27, 4096-4106.
52. Huang J. and Manning B.D. (2009). A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217-222.
53. Huang X., Cho S. and Spangrude G.J. (2007). Hematopoietic stem cells: generation and self-renewal. Cell Death Differ. 14, 1851-1859.
54. Ito K., Hirao A., Arai F., Takubo K., Matsuoka S., Miyamoto K., Ohmura M., Naka K., Hosokawa K., Ikeda Y. and Suda T. (2006). Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12, 446-451.
55. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A. and Hall M.N. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128.
56. Jang Y.Y. and Sharkis S.J. (2007). A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110, 3056-3063.
57. Jeanpierre S., Nicolini F.E., Kaniewski B., Dumontet C., Rimokh R., Puisieux A. and Maguer-Satta V. (2008). BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood 112, 3154-3163.
58. Jia S., Roberts T.M. and Zhao J.J. (2009). Should individual PI3 kinase isoforms be targeted in cancer? Curr. Opin. Cell Biol. 21, 199-208.
59. Kadri Z., Maouche-Chretien L., Rooke H.M., Orkin S.H., Romeo P.H., Mayeux P., Leboulch P. and Chretien S. (2005). Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol. Cell. Biol. 25, 7412-7422.
60. Kalesnikoff J., Sly L.M., Hughes M.R., Buchse T., Rauh M.J., Cao L.P., Lam V., Mui A., Huber M. and Krystal G. (2003). The role of SHIP in cytokine-induced signaling. Rev. Physiol. Biochem. Pharmacol. 149, 87-103.
61. Kashii Y., Uchida M., Kirito K., Tanaka M., Nishijima K., Toshima M., Ando T., Koizumi K., Endoh T., Sawada K., Momoi M., Miura Y., Ozawa K. and Komatsu N. (2000). A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 96, 941-949.
62. Kaushansky K. (2005). The molecular mechanisms that control thrombopoiesis. J. Clin. Invest. 115, 3339-3347.
63. Kaushansky K. (2006). Lineage-specific hematopoietic growth factors. N. Engl. J. Med. 354, 2034-2045.
64. Keniry M. and Parsons R. (2008). The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27, 5477-5485.
65. Kiel M.J. and Morrison S.J. (2008). Uncertainty in the niches that maintain haematopoietic stem cells. Nat. Rev. Immunol. 8, 290-301.
66. Kobayashi M., Laver J.H., Kato T., Miyazaki H. and Ogawa M. (1996). Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 88, 429-436.
67. Kok K., Geering B. and Vanhaesebroeck B. (2009). Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci. 34, 115-127.
68. Kondo M., Weissman I.L. and Akashi K. (1997). Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91, 661-672.
69. Kozuma Y., Kojima H., Yuki S., Suzuki H. and Nagasawa T. (2007). Continuous expression of Bcl-xL protein during megakaryopoiesis is post-translationally regulated by thrombopoietin-mediated Akt activation, which prevents the cleavage of Bcl-xL. J. Thromb. Haemost. 5, 1274-1282.
70. Liu H., Qiu Y., Xiao L. and Dong F. (2006). Involvement of protein kinase Cγ in the negative regulation of Akt activation stimulated by granulocyte colony-stimulating factor. J. Immunol. 176, 2407-2413.
71. Lowry J.A. and Mackay J.P. (2006). GATA-1: one protein, many partners. Int. J. Biochem. Cell Biol. 38, 6-11.
72. Luc S., Buza-Vidas N. and Jacobsen S.E. (2008). Delineating the cellular pathways of hematopoietic lineage commitment. Semin. Immunol. 20, 213-220.
73. Ma L., Chen Z., Erdjument-Bromage H., Tempst P. and Pandolfi P.P. (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193.
74. Ma X.M. and Blenis J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318.
75. Majka M., Janowska-Wieczorek A., Ratajczak J., Kowalska M.A., Vilaire G., Pan Z.K., Honczarenko M., Marquez L.A., Poncz M. and Ratajczak M.Z. (2000). Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood 96, 4142-4151.
76. Mamane Y., Petroulakis E., LeBacquer O. and Sonenberg N. (2006). mTOR, translation initiation and cancer. Oncogene 25, 6416-6422.
77. Manning B.D. and Cantley L.C. (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
78. Martelli A.M., Faenza I., Billi A.M., Manzoli L., Evangelisti C., Fala F. and Cocco L. (2006). Intranuclear 3′-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell. Signal. 18, 1101-1107.
79. Mavrakis K.J., Zhu H., Silva R.L., Mills J.R., Teruya-Feldstein J., Lowe S.W., Tam W., Pelletier J. and Wendel H.G. (2008). Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 22, 2178-2188.
80. Memmott R.M. and Dennis P.A. (2009). Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal. 21, 656-664.
81. Miyakawa Y., Rojnuckarin P., Habib T. and Kaushansky K. (2001). Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J. Biol. Chem. 276, 2494-2502.
82. Miyamoto K., Araki K.Y., Naka K., Arai F., Takubo K., Yamazaki S., Matsuoka S., Miyamoto T., Ito K., Ohmura M., Chen C., Hosokawa K., Nakauchi H., Nakayama K., Nakayama K.I., Harada M., Motoyama N., Suda T. and Hirao A. (2007). Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1, 101-112.
83. Montecino-Rodriguez E., Leathers H. and Dorshkind K. (2001). Bipotential B-macrophage progenitors are present in adult bone marrow. Nat. Immunol. 2, 83-88.
84. Myklebust J.H., Blomhoff H.K., Rusten L.S., Stokke T. and Smeland E.B. (2002). Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells. Exp. Hematol. 30, 990-1000.
85. Nakao T., Geddis A.E., Fox N.E. and Kaushansky K. (2008). PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 7, 257-266.
86. Ong C.J., Ming-Lum A., Nodwell M., Ghanipour A., Yang L., Williams D.E., Kim J., Demirjian L., Qasimi P., Ruschmann J., Cao L.P., Ma K., Chung S.W., Duronio V., Andersen R.J., Krystal G. and Mui A.L. (2007). Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 110, 1942-1949.
87. Orford K.W. and Scadden D.T. (2008). Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat. Rev. Genet. 9, 115-128.
88. Orkin S.H. and Zon L.I. (2008). Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132, 631-644.
89. Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S. and Sabatini D.M. (2009). DEPTOR is an mTOR inhibitor frequently opverexpressed in multiple myeloma cells and required for their survival. Cell 137, 873-886.
90. Raaijmakers M.H. and Scadden D.T. (2008). Evolving concepts on the microenvironmental niche for hematopoietic stem cells. Curr. Opin. Hematol. 15, 301-306.
91. Raslova H., Baccini V., Loussaief L., Comba B., Larghero J., Debili N. and Vainchenker W. (2006). Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood 107, 2303-2310.
92. Reya T., Morrison S.J., Clarke M.F. and Weissman I.L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
93. Robb L. (2007). Cytokine receptors and hematopoietic differentiation. Oncogene 26, 6715-6723.
94. Rojnuckarin P., Miyakawa Y., Fox N.E., Deou J., Daum G. and Kaushansky K. (2001). The roles of phosphatidylinositol 3-kinase and protein kinase C for thrombopoietin-induced mitogen-activated protein kinase activation in primary murine megakaryocytes. J. Biol. Chem. 276, 41014-41022.
95. Ross S.E., Radomska H.S., Wu B., Zhang P., Winnay J.N., Bajnok L., Wright W.S., Schaufele F., Tenen D.G. and MacDougald O.A. (2004). Phosphorylation of C/EBP· inhibits granulopoiesis. Mol. Cell. Biol. 24, 675-686.
96. Sarbassov D.D., Guertin D.A., Ali S.M. and Sabatini D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
97. Schofield R. (1978). The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4, 7-25.
98. Seita J., Ema H., Ooehara J., Yamazaki S., Tadokoro Y., Yamasaki A., Eto K., Takaki S., Takatsu K. and Nakauchi H. (2007). Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc. Natl. Acad. Sci. USA 104, 2349-2354.
99. Shah O.J., Wang Z. and Hunter T. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14, 1650-1656.
100. Shiozawa Y., Havens A.M., Pienta K.J. and Taichman R.S. (2008). The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22, 941-950.
101. Siminovitch L., Till J.E. and McCulloch E.A. (1964). Decline in colony-forming ability of marrow cells subjected to serial transplantation into irradiated mice. J. Cell. Physiol. 64, 23-31.
102. Sitnicka E., Lin N., Priestley G.V., Fox N., Broudy V.C., Wolf N.S. and Kaushansky K. (1996). The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 87, 4998-5005.
103. Sivertsen E.A., Hystad M.E., Gutzkow K.B., Dosen G., Smeland E.B., Blomhoff H.K. and Myklebust J.H. (2006). PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells. Br. J. Haematol. 135,117-128.
104. Soda M., Willert K., Kaushansky K. and Geddis A.E. (2008). Inhibition of GSK-3, promotes survival and proliferation of megakaryocytic cells through a beta-catenin-independent pathway. Cell. Signal. 20, 2317-2323.
105. Sriburi R., Jackowski S., Mori K. and Brewer J.W. (2004). XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J. Cell Biol. 167, 35-41.
106. Stiles B.L. (2009). Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles. Int. J. Biochem. Cell Biol. 41, 757-761.
107. Tamburini J., Chapuis N., Bardet V., Park S., Sujobert P., Willems L., Ifrah N., Dreyfus F., Mayeux P., Lacombe C. and Bouscary D. (2008). Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111, 379-382.
108. Tanaka M., Kirito K., Kashii Y., Uchida M., Watanabe T., Endo H., Endoh T., Sawada K., Ozawa K. and Komatsu N. (2001). Forkhead family transcription factor FKHRL1 is expressed in human megakaryocytes. Regulation of cell cycling as a downstream molecule of thrombopoietin signaling. J. Biol. Chem. 276, 15082-15089.
109. Tothova Z. and Gilliland D.G. (2007). FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 1, 140-152.
110. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., McDowell E.P., Lazo-Kallanian S., Williams I.R., Sears C., Armstrong S.A., Passegue E., DePinho R.A. and Gilliland D.G. (2007). FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128, 325-339.
111. Uddin S., Kottegoda S., Stigger D., Platanias L.C. and Wickrema A. (2000). Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. Biochem. Biophys. Res. Commun. 275, 16-19.
112. von Lindern M., Deiner E.M., Dolznig H., Parren-Van Amelsvoort M., Hayman M.J., Mullner E.W. and Beug H. (2001). Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis. Oncogene 20, 3651-3664.
113. Wang L., Harris T.E. and Lawrence J.C. Jr (2008). Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J. Biol. Chem. 283, 15619-15627.
114. Weissman I.L. and Shizuru J.A. (2008). The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 112, 3543-3553.
115. Wilson A., Laurenti E., Oser G., van der Wath R.C., Blanco-Bose W., Jaworski M., Offner S., Dunant C.F., Eshkind L., Bockamp E., Lio P., Macdonald H.R. and Trumpp A. (2008). Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118-1129.
116. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S. and Workman P. (2008). Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393-412.
117. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H. and Morrison S.J. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482. (Pubitemid 44050144)
118. Yoshihara H., Arai F., Hosokawa K., Hagiwara T., Takubo K., Nakamura Y., Gomei Y., Iwasaki H., Matsuoka S., Miyamoto K., Miyazaki H., Takahashi T. and Suda T. (2007). Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1, 685-697.
119. Yuan T.L. and Cantley L.C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510.
120. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., Wu H. and Li L. (2006). PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518-522.
121. Zhang J. and Lodish H.F. (2005). Identification of K-ras as the major regulator for cytokine-dependent Akt activation in erythroid progenitors in vivo. Proc. Natl. Acad. Sci. USA 102, 14605-14610.
122. Zhao W., Kitidis C., Fleming M.D., Lodish H.F. and Ghaffari S. (2006). Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood 107, 907-915.
123. Zhu D., Hattori H., Jo H., Jia Y., Subramanian K.K., Loison F., You J., Le Y., Honczarenko M., Silberstein L., Luo H.R. (2006). Deactivation of phosphatidylinositol 3,4,5-trisphosphate/Akt signaling mediates neutrophil spontaneous death. Proc. Natl. Acad. Sci. USA 103, 14836-14841.